Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Pharma
ESMO: BMS moves Opdualag into phase 3 trials in 1L NSCLC
BMS has started a phase 3 trial for the drug combo in PD-L1-low NSCLC patients and plans to launch another study in PD-L1-high patients next year.
Angus Liu
Sep 14, 2024 2:40am
AZ set to face tough questions on Imfinzi expansion bid in NSCLC
Jul 24, 2024 8:29am
Bristol Myers’ top challenges, as seen by analysts
Jul 12, 2024 12:00pm
ASCO: BMS' triplet, Iovance's Amtagvi-Keytruda target melanoma
May 23, 2024 5:00pm
Docs ask pharma for more NSCLC drugs, resources and research
Jan 25, 2024 6:30am
Roche hits FDA delay with subcutaneous Tecentriq
Sep 7, 2023 2:46pm
